The purpose of this study was to characterize cytokine responses during conditioning in patients undergoing allogeneic stem cell transplantation (SCT) with the aim to identify which markers that may reliably reflect inflammatory activity during conditioning. We investigated inflammatory and anti-inflammatory mediators in plasma samples drawn daily during the conditioning of 20 patients. Soluble tumour necrosis factor a receptor I (sTNFRI) increased during the conditioning reflecting the type of conditioning given. Antithymocyte globulin (ATG) was the most potent inducer of sTNFRI (288% increase (median) P ¼ 0.002), followed by VP-16 (184%, P ¼ 0.03), cyclophosphamide (129%, P ¼ 0.03) and total body irradiation (148%, P ¼ 0.0005). Administration of i.v. busulfan (Busilvex; BU) was not associated with significant changes in sTNFRI levels. At day 0 (the day of stem cell infusion) the sTNFRI levels were not only elevated compared with baseline (188% increase), Po0.0001), they also correlated with the baseline values (r ¼ 0.72, P ¼ 0.0003). The levels of tumour necrosis factor, interleukin (IL)-1b, IL-6, IL-8, IL-10 and IL-12 stayed at low levels during the conditioning, except from a transient increase in the levels of IL-6, IL-8, IL-10 and IL-receptor antagonist (IL-Ra) seen after ATG infusion. These findings suggest that further investigation of circulating sTNFRI levels may be of interest in studies of prognostic factors in SCT.
Introduction
Allogeneic stem cell transplantation (SCT) may be associated with a variety of complications that may lead to progressive functional deterioration and subsequent death. 1 In addition to acute graft-versus-host disease (aGvHD), the major non-infectious transplant-related complications (TRC) seen during the first 100 days following SCT include veno-occlusive disease, idiopathic pneumonia syndrome, and multiorgan dysfunction syndrome. Overall, about 50% of the mortality after SCT may be ascribed to TRC. 2 The reasons why only some patients develop such complications are unclear. The concept of a 'cytokine storm' as a major cause of TRC is now well established. This is primarily based on studies in mice that have provided evidence that the conditioning regimen induces the release of inflammatory cytokines as well as tissue damage. These, in combination, are thought to initiate an inflammatory response, that may be further propagated by the influx of endotoxins from the inflamed and injured intestine. [3] [4] [5] In addition to the studies in animals, a number of previous studies have focused on cytokine profiles in humans undergoing SCT, but the conclusions that can be drawn from these studies are less clear. Elevated serum levels of immunoregulating and inflammatory cytokines, such as tumour necrosis factor (TNF), interleukin (IL)-1b, IL-8 and interferon-g, have been observed before and during these complications. 6, 7 In particular, TNF has been the focus of a number of studies and there are indications that high serum levels of TNF in the early phases of SCT are related to an increased risk of severe aGvHD. 8 Moreover, TNF antagonists, such as anti-TNF antibody, may partially prohibit the development of aGvHD. 9, 10 In contrast, a number of other investigators have found that TNF levels are normal during conditioning and of no prognostic significance. [11] [12] [13] [14] [15] These divergences may relate to differences in the patient population, the treatment regimens, or the assays applied. Also the time of sampling may be essential as indicated by data from Holler et al. 10 showing fluctuating levels of TNF depending on the type of conditioning and on the time of sampling.
Tumour necrosis factor exerts its biological activities through binding to the specific cell surface receptors, TNFRI and TNFRII. Activation of cells by for example, IL-1, IL-8 or by TNF is followed by the release of soluble, truncated versions of TNF receptors (sTNFRI and -II) consisting of only the extracellular ligand-binding domains. The biological roles of these receptors are not definitely clarified. The shedding of sTNFR's and the resultant decrease in TNFR's on the cell surface may serve to transiently desensitise cells, thereby inhibiting TNF activity, and the soluble receptors may block TNF bioactivities by binding to the molecule, preventing ligand binding to the cellular TNFR's. Hence, the appearance of extracellular soluble receptors may represent a regulatory mechanism for modulation of excessive TNF activity. [16] [17] [18] On the other hand, the binding of TNF is reversible, and the complexes of TNF with soluble receptors that are less readily cleared than free TNF, may prolong the retention of TNF in the circulation, and thereby allow a prolonged effect of released TNF. 19 This may be of potential pathophysiological significance in infectious and inflammatory diseases. 20, 21 Indeed, a previous study has suggested that high levels of sTNFR before/during conditioning may be prognostic for the outcome in SCT, and a polymorphism in the TNFRII gene is associated with mortality after SCT. 22 As a step towards a better understanding of the significance of the inflammatory responses during SCT we have gathered more detailed information on cytokine responses during conditioning. Our aim was to characterise the impact of different conditioning regimens on cytokine responses and to identify inflammatory mediators that may reliably reflect the inflammatory response during SCT. We investigated sTNFRI and -II levels as well as a broad range of immunoregulating and inflammatory cytokines (incl. TNF IL-1b, IL-8, IL-10 and IL-1 receptor antagonist (IL-1Ra)) in blood samples taken daily from the start of conditioning till the infusion of stem cells.
Patients and methods

Patients and donors
Twenty patients (10 females and 10 males) undergoing SCT at the National University Hospital in Copenhagen were included in the study. The patient characteristics and the conditioning regimens are presented in Table 1 . The ages of the patients were 0-15 years (n ¼ 7), 16-35 (n ¼ 8) and 36-60 (n ¼ 5). Eleven patients were transplanted with grafts from matched unrelated donors (MUD) while nine patients were transplanted with cells from sibling donors. Eleven recipients were transplanted for ALL, six for AML and three patients were transplanted for non-malignant diseases. The patients were followed until 1 year after the transplant with registration of mortality, aGvHD and chronic graft-versus-host disease (cGvHD).
The conditioning regimens included total body irradiation (TBI) (4 Gy for 3 days; total dose 12 Gy), cyclophosphamide (CY) (total dose 120-200 mg/kg), i.v. busulfan (Busilvex; BU) (Pierre Fabre, Paris, France) 0.8 mg/kg four times daily i.v. for 4 consecutive days; total dose 12.8 mg/kg or VP-16 (etoposide) 60 mg/kg once i.v.; total dose 60 mg/ kg ( Table 1) . None of the patients received low-intensity conditioning. Patients transplanted with MUD received additional immunosuppression with antithymocyte globulin (ATG) (Thymoglobulin (2.5 mg/kg once daily i.v. for 3 consecutive days, total dose 7.5 mg/kg (at day À5, À4 and À3 before the transplant). Cyclosporin A (initial dose 12.5 mg/kg/day) with four doses of methotrexate (at day 1, 4, 6, 11) in the case of MUD was given as prophylaxis against GvHD. No ex vivo T-cell depletion was employed.
Plasma samples
Heparin plasma samples were drawn daily in the morning from central venous catheters, from before conditioning and through to day 0. The samples were kept at 51C for a maximum of 2 h, followed by centrifugation, and plasma was stored at À801C until analysis. The samples were stored for a maximum of 4 months before being assayed for cytokines and cytokine receptors. 
Cytokine assays
Interleukin-1b, IL-6, IL-8, IL-10, IL-12p70 and TNF were measured in 1:2 diluted plasma samples by flow cytometric bead arrays according to the instructions of the manufacturer (Becton Dickinson, Brnby, Denmark). Detection limit for IL-1b was 50 pg/ml, and for IL-6, IL-8, IL-10, IL-12p70 and TNF 5 pg/ml. Assay variations were o5%.
Enzyme-linked immunosorbent assay (ELISA) for sTNFRI and -II sTNFRI and -II were measured in 1:2 diluted plasma samples by ELISA (R&D, Minneapolis, USA) according to the instructions by the manufacturer. This assay measures the total amount of free receptor plus the total amount of receptor bound to TNF. Detection limits for both assays were 20 pg/ml.
Enzyme-linked immunosorbent assay for interleukin-receptor antagonist
Interleukin-1Ra (IL-1Ra) was measured by a double sandwich ELISA using monospecific polyclonal rabbit antibodies to purified recombinant IL-1Ra as detailed. 23 Briefly, Immuno-Maxisorb plates (Nunc, Roskilde, Denmark) were coated with protein-A affinity-purified IgG. Non-attached sites were blocked with 1% human serum albumin in phosphate-buffered saline. The assays were calibrated with international standards of the respective cytokines (National Institute for Biological Standards and Controls (NIBSC), Potters Bar, Hertfordshire, UK). Biotinylated rabbit antibodies were used as detecting antibodies along with streptavidin peroxidase (Kirkegaard and Perry La., Gaithersburg, MD, USA). Development was carried out with 1,2-phenylenediamine dihydrochloride and measured at 492 nm. The inter-and intra-assay coefficients of variation for the concentration range between 15 pg/ml and 1 ng/ml were o15%. The limit of sensitivity of this ELISA was 30 pg/ml.
Statistics
Differences between paired and unpaired samples were evaluated using the Wilcoxon and the Mann-Whitney tests, respectively. Correlations were tested using the Spearman's correlation coefficient. The level of significance was chosen to 5%. The study was approved by the regional ethics committee.
Results
Plasma levels of sTNFRI and -II sTNFRI was measured at baseline (at day À7 before the start of conditioning), and daily until day 0 before infusion of the transplant. At baseline sTNFRI levels did not differ significantly between SCT patients and healthy age matched controls (Figure 1 ). After initiation of the conditioning, variable levels of sTNFRI were observed, reflecting the type of conditioning given in a very reproducible way (Figure 2 ). Antithymocyte globulin, VP-16, TBI and cyclophosphamide (CY) all induced significant increases in the levels of sTNFRI, but ATG appeared to be the most potent inducer of sTNFRI. The impact of CY and TBI were moderate and administration of BU was not associated with significant changes in sTNFRI levels.
At the day of stem cell infusion, the sTNFRI levels were significantly elevated compared with baseline values, and correlated significantly with those (Figures 1  and 3) . The levels at day 0 tended to be higher in patients treated with ATG than in patients not treated with ATG ( Figure 4 ). The findings for sTNFRII at day À7 and at day 0 followed the same pattern as that seen for sTNFRI ( Figures  1, 3, 4) .
Associations between the sTNFR levels and the clinical outcome after stem cell transplantation The levels of sTNFRI and -II were not associated with aGvHD or cGvHD within 1 year after transplantion. The limited number of patients and the heterogeneity in conditioning regimens did not allow an appropriate statistical analysis of mortality, but is was noticeable that the three patients who died due to treatment-related complications (at day 21, 62 and 154) had the three highest sTNFRI levels observed at day 0 as well as prior to conditioning (Figure 3 ).
Inflammatory and immunoregulating cytokines
Screening of daily taken plasma samples for the presence of TNF, IL-1b, IL-6, IL-8, IL-10, IL-12 and IL-1Ra did not indicate any generalized increase during conditioning. However, in the days after ATG infusion a clear, albeit transient, increase in the levels of IL-6, IL-8, IL-10 and IL1Ra, was observed ( Figure 5 ). Interleukin-6 and IL-8 levels after the first ATG infusion correlated positively (r ¼ 0.92; P ¼ 0.0005), while no significant correlations between the levels of IL-6 and IL-8 and the anti-inflammatory mediators, IL-10 and IL-1Ra, were observed (not shown). Treatment with ATG was accompanied by variable degrees of general malaise including fever and tachycardia, but there was no significant correlation between cytokine levels Figure 5 Differential impact of treatment modalities on cytokine levels sTNFRI levels during conditioning in patients undergoing stem cell transplantation (SCT). Clear bars: levels immediately before start of each treatment modality; spotted bars: 1 day after start of each treatment modality; hatched bars: 2 days after start of each treatment modality (medians and ranges). Interleukin (IL)-6: total body irradiation (TBI) (a) P ¼ 0.02 (before versus day 1), ATG (b) P ¼ 0.002 (before versus day 1), CY (c) P ¼ 0.03 (days 1 versus 2). Interleukin-8: TBI (a) P ¼ 0.02 (before versus day 1); ATG (b) P ¼ 0.002 (before versus day 1), VP16 (c) P ¼ 0.03 (day 0-1). Interleukin-10: ATG (a) P ¼ 0.002 (before versus day 1). Interleukin-1Ra: TBI (a) P ¼ 0.02 (before versus day 1); ATG (b) P ¼ 0.002 (before versus day 1). TBI: total body irradiation (n ¼ 12), ATG: antithymocyte globulin (ATG) (n ¼ 10), VP-16: etoposide (n ¼ 6), CY: cyclophosphamide (n ¼ 7), BU: i.v. busulfan (n ¼ 5). The levels of these cytokines were either close to or below the detection limit at the day of stem cell infusion. Tumour necrosis factor and IL-1b were below the detection limit through the whole period of conditioning. and the severity of these clinical manifestations (not shown). The levels of these cytokines were either close to or below the detection limit at the day of stem cell infusion (day 0).
Notably, both TNF and IL-1b stayed below -or close to the detection limit throughout the conditioning and at day 0. This was also seen in patients treated with ATG (not shown).
Discussion
The aim of the present investigation was to characterize cytokine responses during the conditioning of patients undergoing SCT, in order to identify reliable markers of inflammation and to examine the impact of different conditioning regimens on the inflammatory response. We focused on sTNFRI and -II levels as markers of cytokineinduced inflammation for several reasons. First, sTNFRI and -II have longer half-lives than TNF and other inflammatory cytokines, and it is present at higher concentrations, well within the detection range of most immunometric assays, even in healthy individuals. Moreover, sTNFRI and -II have been found elevated in a wide range of inflammatory conditions, including GvHD, and correlate with inflammatory activity in diseases, where correlations for TNF has been difficult to establish. Third, sTNFR appear to be an interesting mediator due to previous studies showing a prognostic significance of elevated sTNFR levels as well as polymorphisms in the TNFRII gene. 22, 24 The presented data indicated that sTNFR levels are generally increased during conditioning in patients undergoing SCT. Of further interest, sTNFRI levels remained elevated at day 0. Thus, it may be of interest to identify factors influencing the levels of sTNFRI. We found that the sTNFRI levels were determined by two factors. First, sTNFRI levels appeared to be influenced by the composition of the conditioning regimen. The various treatment modalities studied here, differed significantly in their impact on sTNFRI release, with ATG and VP-16 at the high end, CY and TBI in the intermediate zone, and BU at the low end. In particular, sTNFRII levels appeared to be higher at day 0 in patients treated with ATG. These findings are in line with the fact that BU treatment is associated with relatively few symptoms of toxicity. 25 Moreover, these observations are consistent with previous studies of cytokine profiles in BU-CY-or TBI-treated mice, 3 and suggest that monitoring sTNFRI may provide information about the toxic potential of drug combinations planned for pre-transplant conditioning.
The observed correlation between post-conditioning levels and baseline levels of sTNFRI suggests that the release of TNFRI during conditioning and at day 0 is partly influenced by factors determined before the start of conditioning. Such factors may include recent chemotherapy and recent bacterial or viral infections. In healthy individuals we did not observe any age-related differences, but among the patients sTNFRI levels were significantly higher in adults than in children. Moreover, genetic factors may influence the dynamics within the TNF system including single nucleotide polymorphisms and microsatellites in the promoters or in the coding sequences of the TNF gene influencing the production and function of TNF. 26 In fact, signalling by TNFRII, 27 as well as the plasma levels of sTNFRII has been found to vary according to TNFRII genotypes, and both TNF and TNFRII genotypes may be related to the outcome in SCT, including the risk of GvHD, 5, 22 Moreover, the dynamics of the TNF system may be influenced by polymorphisms in the exons of the thymic stromal lymphopoitin receptor and in the IL-7 receptor that appears to be strongly associated with treatment-related mortality. 28, 29 In line with the conclusions in previous studies, 22, 24 there was a trend towards higher mortality in patients with high sTNFRI and -II levels, suggesting that monitoring of sTNFRI at day 0 may be clinically relevant as a prognostic marker for the outcome in SCT. The patient population studied here was, however, heterogeneous and it cannot be excluded that statistical interactions between pre-transplant parameters, the choice of conditioning regimens and the outcome parameters may have influenced the observations on this point. For a sufficient evaluation of possible associations between sTNFRI levels and the outcome in SCT studies of larger cohorts are needed.
Increases in the levels of immunoregulating and inflammatory cytokines were only transient, and the plasma concentrations were generally below levels at which biological activities are likely to occur. Importantly, we did not observe any increase in the circulating levels of TNF, in agreement with a number of previous studies, [11] [12] [13] [14] [15] but in contrast to some studies. 8 These apparent divergences may relate to differences in the patient populations studied, their underlying diseases, previous infections, the type of conditioning and the assays applied. Thus, certain monoclonal antibodies may recognize epitopes on TNF that are masked by the binding of TNF to sTNFR, and this may lead to failure of detection of TNF. This may also apply to the assay used in the present study. In addition, as suggested by the data of the present study, differences in the days of sampling may lead to major differences in the findings.
Cytokine responses during conditioning are thought to play a key role in the pathogenesis of aGvHD either via direct activation on the donor cells, or indirectly via enhanced expression of class I and II antigens by recipient cells. 5, 30 On the day of stem cell infusion, however, the examined inflammatory cytokines were found at levels that are not likely to induce significant stimulation of cells, suggesting that the circulating cytokines at the day of transplantation are unlikely to directly affect the function of infused donor T cells.
In conclusion, our data indicate that 'the cytokine storm' induced during inflammation may be reliably monitored by sTNFRI levels. The finding that sTNFRI levels are influenced by the type of conditioning as well as by individual factors determined before the start of conditioning, suggest that sTNFRI may be an interesting marker for studies of the prognostic significance of treatment-induced inflammation in SCT.
